Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology to bring hope to the estimated 58% of AML patients for …